| Host |
Mouse |
| Clone |
CEA31 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human colon carcinoma extract |
| Localization |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
0.1 ml |
Concentrate |
CE/IVD |
Z2100MT |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Human colon carcinoma extract |
| Localization |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
1.0 ml |
Concentrate |
CE/IVD |
Z2565RL |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon carcinoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Human colon carcinoma extract |
| Localization |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
Z2565RP |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Human colon carcinoma extract |
| Localization |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
Z2565RS |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Human colon carcinoma extract |
| Localization |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
Z2565RT |
-
|
| Host |
Rabbit |
| Clone |
DBRRM2.85 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Colon Carcinoma |
| Dilution |
1:100-1:200 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human CEA protein fragment |
| Localization |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB118R |
-
|
| Host |
Rabbit |
| Clone |
DBRRM2.85 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Colon Carcinoma |
| Dilution |
1:100-1:200 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human CEA protein fragment |
| Localization |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB118R-01 |
-
|
| Host |
Rabbit |
| Clone |
DBRRM2.85 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Colon Carcinoma |
| Dilution |
1:100-1:200 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human CEA protein fragment |
| Localization |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB118R-05 |
-
|
| Host |
Rabbit |
| Clone |
DBRRM2.85 |
| Format |
ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Colon Carcinoma |
| Dilution |
--- |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human CEA protein fragment |
| Localization |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD118R |
-
|
| Host |
Rabbit |
| Clone |
ZR370 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
HIER or PIER |
| Positive control |
Colon Carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Recombinant full-length human CEA protein |
| Localization |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
1 ml |
Concentrate |
CE/IVD |
Z2661RL |
-
|
| Host |
Rabbit |
| Clone |
ZR370 |
| Format |
ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
HIER or PIER |
| Positive control |
Colon Carcinoma |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Immunogen |
Recombinant full-length human CEA protein |
| Localization |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
7 ml |
ready-to-use |
CE/IVD |
Z2661RP |
-
|
| Host |
Rabbit |
| Clone |
ZR370 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
HIER or PIER |
| Positive control |
Colon Carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Recombinant full-length human CEA protein |
| Localization |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
0.5 ml |
Concentrate |
CE/IVD |
Z2661RS |
-
|
| Host |
Rabbit |
| Clone |
ZR370 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
HIER or PIER |
| Positive control |
Colon Carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Recombinant full-length human CEA protein |
| Localization |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
0.1 ml |
Concentrate |
CE/IVD |
Z2661RT |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Trypsin |
| Positive control |
Small Intestine |
| Dilution |
1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide sulfated cholecystokinin (26-33) amide (sulfated CCK-8). |
| Localization |
Cytoplasmic, Lumenal Membrane |
Cholecystokinin (26-33)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-4514 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Purified |
| Method |
EL, IP |
| Isotype |
Rabbit IgG |
| Immunogen |
Purified Choleragenoid |
Cholera Toxin (beta Subunit)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
603-1886 |
-
|
| Host |
Mouse |
| Clone |
LK2H10+PHE5 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
CC1 |
| Positive control |
Pancreas, Adrenal gland |
| Dilution |
- |
| Isotype |
Mouse IgG1+ Mouse IgG1 |
| Localization |
Cytoplasm |
Chromogranin A
|
Biocare Medical |
LK2H10+PHE5 |
6 ml |
Ready-to-use |
CE/IVD |
AVI010G |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Pancreas |
| Dilution |
1:25 - 1:50 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP008 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Pancreas |
| Dilution |
1:25 - 1:50 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP008-01 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Pancreas |
| Dilution |
1:25 - 1:50 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP008-05 |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM12 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pancreas or neuroendocrine tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human Chromogranin A protein |
| Localization |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
1 ml |
Concentrate |
CE/IVD |
Z2347ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM12 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pancreas or neuroendocrine tumor. |
| Dilution |
- |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human Chromogranin A protein |
| Localization |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
7 ml |
Ready-to-use |
CE/IVD |
Z2347MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM12 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pancreas or neuroendocrine tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human Chromogranin A protein |
| Localization |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
0.5 ml |
Concentrate |
CE/IVD |
Z2347MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM12 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pancreas or neuroendocrine tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human Chromogranin A protein |
| Localization |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
0.1 ml |
Concentrate |
CE/IVD |
Z2347MT |
-
|
| Host |
Mouse |
| Clone |
4E1 |
| Format |
Purified |
| Method |
F, P, WB, EL |
| Isotype |
Mouse IgG3 |
| Immunogen |
Native pancreatic |
Chymotrypsin
|
Zytomed Systems GmbH |
4E1 |
200 µg |
Purified |
RUO |
603-1908 |
-
|
| Host |
Mouse+Rabbit |
| Clone |
34ßE12+4A4+13H4 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Reveal modified Citrate pH 6.0 or pH 6.2 |
| Positive control |
Prostate intraepithelial neoplasia PIN |
| Dilution |
- |
| Isotype |
MouseIgG1/kappa+IgG2a+RabbitIgG |
| Localization |
Cytoplasmic and nuclear |
CK HMW + p63 + AMACR (RM)
|
Biocare Medical |
34ßE12+4A4+13H4 |
6 ml |
Ready-to-use |
CE/IVD |
API3154DSAA |
-
|
| Host |
Mouse+Rabbit |
| Clone |
34ßE12+4A4+13H4 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Reveal modified Citrate pH 6.0 or pH 6.2 |
| Positive control |
Prostate intraepithelial neoplasia PIN |
| Dilution |
- |
| Isotype |
MouseIgG1/kappa+IgG2a+RabbitIgG |
| Localization |
Cytoplasmic and nuclear |
CK HMW + p63 + AMACR (RM)
|
Biocare Medical |
34ßE12+4A4+13H4 |
25 ml |
Ready-to-use |
CE/IVD |
API3154DSH |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Skin, Breast Carcinoma |
| Dilution |
1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide derived from the C-terminus of human Claudin-1. |
| Localization |
Cell Membrane on Skin, Cytoplasmic/Nuclear on Mamma |
Claudin 1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-3414 |
-
|
| Host |
Rabbit |
| Clone |
SP128 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Liver, hepatocellular carcinoma |
| Dilution |
1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
| Localization |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
0.1 ml |
Concentrate |
RUO |
503-4280 |
-
|
| Host |
Rabbit |
| Clone |
SP128 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Liver, liver carcinoma |
| Dilution |
1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
| Localization |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
0.5 ml |
Concentrate |
RUO |
503-4282 |
-
|
| Host |
Rabbit |
| Clone |
SP128 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Liver, liver carcinoma |
| Dilution |
1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
| Localization |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
1 ml |
Concentrate |
RUO |
503-4284 |
-
|
| Host |
Mouse |
| Clone |
3E2C1 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Colon carcinoma or breast carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
| Localization |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3121A |
-
|
| Host |
Mouse |
| Clone |
3E2C1 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Colon carcinoma or breast carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
| Localization |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3121B |
-
|
| Host |
Mouse |
| Clone |
3E2C1 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Colon carcinoma or breast carcinoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Immunogen |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
| Localization |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
6 ml |
Ready-to-use |
CE/IVD |
API3121AA |
-
|
| Host |
Rabbit |
| Clone |
DBRRM1.82 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Stomach |
| Dilution |
1:50-1:100 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
| Localization |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB116R |
-
|
| Host |
Rabbit |
| Clone |
DBRRM1.82 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Stomach |
| Dilution |
1:50-1:100 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
| Localization |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB116R-01 |
-
|
| Host |
Rabbit |
| Clone |
DBRRM1.82 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Stomach |
| Dilution |
1:50-1:100 |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
| Localization |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB116R-05 |
-
|
| Host |
Rabbit |
| Clone |
DBRRM1.82 |
| Format |
ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Stomach |
| Dilution |
--- |
| Isotype |
IgG kappa |
| Immunogen |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
| Localization |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD116R |
-
|
| Host |
Rabbit |
| Clone |
ZR451 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Carcinomas |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
| Localization |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
1 ml |
Concentrate |
RUO |
Z2807RL-R |
-
|
| Host |
Rabbit |
| Clone |
ZR451 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Carcinomas |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
| Localization |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
7 ml |
Ready-to-use |
RUO |
Z2807RP-R |
-
|
| Host |
Rabbit |
| Clone |
ZR451 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Carcinomas |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
| Localization |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
0.5 ml |
Concentrate |
RUO |
Z2807RS-R |
-
|
| Host |
Rabbit |
| Clone |
ZR451 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Carcinomas |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
| Localization |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
0.1 ml |
Concentrate |
RUO |
Z2807RT-R |
-
|
| Host |
Rabbit |
| Clone |
ZR456 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
CMV infected tissue |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant CMV-p65 protein |
| Localization |
Nucleus/cytoplasmic |
CMV
|
Zeta Corporation |
ZR456 |
1 ml |
Concentrate |
RUO |
Z2818RL-R |
-
|
| Host |
Rabbit |
| Clone |
ZR456 |
| Format |
RTU |
| Reactivity |
- |
| Method |
P |
| Positive control |
CMV infected tissue |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant CMV-p65 protein |
| Localization |
Nucleus/cytoplasmic |
CMV
|
Zeta Corporation |
ZR456 |
7 ml |
RTU |
RUO |
Z2818RP-R |
-
|
| Host |
Rabbit |
| Clone |
ZR456 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
CMV infected tissue |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant CMV-p65 protein |
| Localization |
Nucleus/cytoplasmic |
CMV
|
Zeta Corporation |
ZR456 |
0.5 ml |
Concentrate |
RUO |
Z2818RS-R |
-
|
| Host |
Rabbit |
| Clone |
ZR456 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
CMV infected tissue |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant CMV-p65 protein |
| Localization |
Nucleus/cytoplasmic |
CMV
|
Zeta Corporation |
ZR456 |
0.1 ml |
Concentrate |
RUO |
Z2818RT-R |
-
|
| Host |
Mouse |
| Clone |
9E10 |
| Format |
Purified |
| Method |
F, P, EL, WB |
| Isotype |
Mouse IgG1 |
| Immunogen |
Synthetic peptide sequence AEEQKLISEEDLL corresponding to the C-terminal region of human c-myc |
cMyc
|
Zytomed Systems GmbH |
9E10 |
1 mg |
Purified |
RUO |
603-1940 |
-
|
| Host |
Mouse |
| Clone |
9E10 |
| Format |
Purified |
| Method |
F, P, EL |
| Isotype |
Mouse IgG1 |
| Immunogen |
Synthetic peptide sequence AEEQKLISEEDLL corresponding to the C-terminal region of human c-myc |
cMyc
|
Zytomed Systems GmbH |
9E10 |
100 µg |
Purified |
RUO |
603-1941 |
-
|
| Host |
Rabbit |
| Clone |
EP121 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Some prostate or breast cancers |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to residues in N-terminus of human c-Myc |
| Localization |
Nucleus |
cMyc
|
Biocare Medical |
EP121 |
0.1 ml |
Concentrate |
CE/IVD |
CME415AK |
-
|
| Host |
Mouse |
| Clone |
9E10 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Breast carcinoma, colon adenocarcinoma |
| Dilution |
1:50 - 1 :100 |
| Isotype |
IgG 1 kappa |
| Immunogen |
f human c-Myc |
| Localization |
Nucleus |
cMyc
|
Diagnostic Biosystems |
9E10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM211 |
-
|
| Host |
Mouse |
| Clone |
9E10 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Breast carcinoma, colona adenocarcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
IgG1 kappa |
| Immunogen |
f human c-Myc |
| Localization |
Nucleus |
cMyc
|
Diagnostic Biosystems |
9E10 |
25 ml |
Ready-to-use |
CE/IVD |
PDM211-25 |
-
|